1. Zhu, Ke, Xu, Aiqun, Xia, Wanli, Zhou, Sijing, Wang, Ran. 2021. Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis. In Frontiers in oncology, 11, 567762. doi:10.3389/fonc.2021.567762. https://pubmed.ncbi.nlm.nih.gov/33777732/
2. Jiang, W-H, Wang, X-T, Zheng, L-D, Yan, Q-Q, Chen, L-L. . Relationship between NAT2 polymorphisms and onset risk of acute leukemia: a systematic review and meta-analysis. In European review for medical and pharmacological sciences, 23, 9259-9266. doi:10.26355/eurrev_201911_19418. https://pubmed.ncbi.nlm.nih.gov/31773677/
3. Mohamed Noor, Nur Farhana, Salleh, Mohd Zaki, Mohd Zim, Mohd Arif, Lailanor, Muhammad Imran, Teh, Lay Kek. 2022. NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity. In Pharmacogenomics, 23, 531-541. doi:10.2217/pgs-2022-0022. https://pubmed.ncbi.nlm.nih.gov/35615896/
4. Yee, Jeong, Kim, So Min, Han, Ji Min, Yoon, Ha Young, Gwak, Hye Sun. 2020. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. In Scientific reports, 10, 3658. doi:10.1038/s41598-020-60467-8. https://pubmed.ncbi.nlm.nih.gov/32107440/
5. Wang, P-Y, Xie, S-Y, Hao, Q, Zhang, C, Jiang, B-F. 2012. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. In The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16, 589-95. doi:10.5588/ijtld.11.0377. https://pubmed.ncbi.nlm.nih.gov/22409928/
6. Jaramillo-Valverde, Luis, Levano, Kelly S, Tarazona, David D, Ugarte-Gil, Cesar, Guio, Heinner. 2022. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. In Molecular genetics & genomic medicine, 10, e1987. doi:10.1002/mgg3.1987. https://pubmed.ncbi.nlm.nih.gov/35751408/
7. Wichukchinda, Nuanjun, Pakdee, Jirapa, Kunhapan, Punna, Tokunaga, Katsushi, Mahasirimongkol, Surakameth. 2020. Haplotype-specific PCR for NAT2 diplotyping. In Human genome variation, 7, 13. doi:10.1038/s41439-020-0101-7. https://pubmed.ncbi.nlm.nih.gov/32411379/
8. Jiménez-Jiménez, Félix Javier, Alonso-Navarro, Hortensia, García-Martín, Elena, Agúndez, José A G. 2016. NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis. In Expert opinion on drug metabolism & toxicology, 12, 937-46. doi:10.1080/17425255.2016.1192127. https://pubmed.ncbi.nlm.nih.gov/27216438/
智鼠故事 
